Drug
Short Course Radiotherapy
Short Course Radiotherapy: highest development phase Phase 2, developed by Junshi Biosciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Junshi Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| Short-course Radiotherapy, SCRT NCT07669220 | Phase 2 | Rectal Adenocarcinoma |
Latest
No recent events.
Follow Short Course Radiotherapy on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.